Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of Temsirolimus in patients
with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy.